Wikipedia

Cobalamin riboswitch

(Redirected from AdoCbl riboswitch)

Cobalamin riboswitch is a cis-regulatory element which is widely distributed in 5' untranslated regions of vitamin B12 (Cobalamin) related genes in bacteria.[1]

Cobalamin riboswitch
Predicted secondary structure and sequence conservation of Cobalamin
Identifiers
SymbolCobalamin
RfamRF00174
Other data
RNA typeCis-reg; riboswitch
Domain(s)Bacteria
SOSO:0000035
PDB structuresPDBe 6VMY

Cobalamin (vitamin B12, coenzyme B12 ) riboswitches are structured RNA elements that regulate adjacent genes related to cobalamin metabolism in response to cobalamin binding. Riboswitches are RNA-based genetic regulatory elements present in the 5’ untranslated region (5'UTR) of primarily bacterial RNA. These switches bind to a ligand, which is generally a metabolite, with high affinity and specificity.  Ligand binding mediates allosteric rearrangement of mRNA structure, and this results in modulation of gene expression or translation of mRNA to yield a protein. The cobalamin riboswitch, along with most other riboswitches, are cis-regulatory. This means they regulate genes involved in the same metabolic pathways as the metabolite they bind, which creates regulation through a negative feedback loop. Riboswitches are grouped into classes by the ligand that they bind because the ligand-binding or aptamer domain is highly conserved across species. Riboswitches, including the cobalamin riboswitch, have garnered a lot of attention recently due to their therapeutic and synthetic potential,[2] as well as their interesting structural properties.[3][4][5] As of 2019, cobalamin riboswitches have been identified in over 5000 species of bacteria.[2]

Ligand selectivity

edit

Cobalamin riboswitches bind cobalamin (vitamin B12), which is a complex enzyme cofactor composed of a corrin ring coordinated to a cobalt (III) ion. In the alpha-axial position, the cobalt is coordinated to a dimethylbenzimidazole moiety attached to the corrin ring via a flexible aminopropanol linker.[6][7] The active portion of the cofactor is in the beta-axial position. Methylcobalamin (MeCbl) and adenosylcobalamin (AdoCbl) are the biologically active forms of cobalamin, containing a methyl group and an adenosyl moiety in the beta-axial position, respectively.[6] Hydroxocobalamin (HyCbl), with a hydroxyl group in the beta-axial position, is produced as a result of cobalamin photolysis, and is present in biological conditions but is not in an active form. Cyanocobalamin (CyCbl) is an artificial form of cobalamin found in supplements, which can be converted to active forms of cobalamin. Cobalamin riboswitches can exhibit selectivity toward different forms of cobalamin.[6]

Structure and classes

edit

Riboswitches, including the cobalamin riboswitch, are generally composed of a ligand-binding or aptamer domain and an expression platform. Ligand binding induces an allosteric structural rearrangement in the expression platform that results in the regulation of gene expression via transcriptional or translational mechanisms.[4][8]

Class I (Cbl-I)

edit

Cobalamin riboswitches are broadly classified by the identity of the aptamer, but can be further classified into Class I (Cbl-I) and Class II (Cbl-II) based on cobalamin analogue selectivity and peripheral structural elements.[6] Cbl-I and Cbl-II riboswitches share a conserved receptor domain composed of a four-way junction and regulatory domain. Cbl-I riboswitches are selective for AdoCbl, with a variable peripheral stem loop structure facilitating ligand specificity.[6][9] Over 90% of cobalamin riboswitches identified before 2003 are Cbl-I riboswitches.[10]

Class IIa (Cbl-IIa)

edit
 
VB12-bound Riboswitches with PDB codes: a) 4FRN b) 6VMY c) 4FRG d) 4GMA

Cbl-II can be further divided into two classes (Cbl-IIa and Cbl-IIb). Cbl-IIa riboswitches are specific to cobalamin analogues with smaller β-axial ligands including MeCbl and HyCbl.[6][9] This selectivity is determined by peripheral element variations.[6]

Class IIb (Cbl-IIb)

edit

Cbl-IIb riboswitches are also selective for AdoCbl,[6][9] but they differ significantly in structure from Cbl-I riboswitches. The structural basis for AdoCbl selectivity has not yet been determined.[6] Cbl-IIb riboswitches also differ in terms of the nature of the genes they regulate, with Cbl-IIb riboswitches primarily associated with genes involved in ethanolamine utilization.[6] Ethanolamine is abundant in the human intestinal tract as it is the product of the breakdown of the phosphatidylethanolamine from cell membranes and is also present in processed food. Most bacteria that inhabit the intestinal tract can utilize ethanolamine as a carbon and nitrogen source by upregulating the expression of the ethanolamine utilization genes; this may have a survival advantage.[11] The expression of the ethanolamine utilization genes (eutG) is influenced by two different mechanisms. The first is a two component regulatory system that senses the presence of ethanolamine and the second mechanism is an AdoCbl riboswitch that senses the presence of AdoCbl, a cofactor needed for the breakdown of ethanolamine. A study showed that both these regulatory elements need to be activated for the bacteria to grow efficiently on medium containing ethanolamine.[12] Bioinformatic studies were initially unsuccessful in identifying AdoCbl riboswitches within the bacteria genomes, but subsequent studies of the intergenic regions of the eutG locus using Ribex identified an RNA element between the eutT and eutG genes.[1][13]

In addition, some cobalamin riboswitches exhibit promiscuous ligand binding, such as the B. subtilis yvrC riboswitch, which can adopt different structural conformations in order to bind cobalamin analogues with smaller β-axial ligands such as MeCbl and HyCbl in addition to AdoCbl, which has a much bulker β-axial moiety.[9] This riboswitch is also capable of binding CyCbl.[9]

Discovery

edit

Before proof of riboswitch function, a conserved sequence motif called the B12 box[14] was identified that corresponds to a part of the cobalamin riboswitch,[1] and a more complete conserved structure was identified.[10][8] Variants of the riboswitch consensus have been identified.[15] Before a broader range of cobalamin riboswitches were identified, it was believed that only AdoCbl riboswitches existed.[10]

Mechanism

edit

The mechanisms of individual cobalamin riboswitches can vary and many have not yet been elucidated.[16] The four canonical mechanisms for riboswitches include transcriptional activation or repression and translational activation or repression.[17][16] In transcriptional activation, a terminator loop, which blocks the RNA polymerase binding site, is present in the absence of ligand and upon ligand binding, an anti-terminator loop forms and the terminator hairpin is removed. Transcriptional termination occurs when the terminator stem loop forms in the presence of a ligand. Regulation via translational activation occurs when the Shine-Dalgarno (SD) sequence, necessary for the ribosome to bind to the mRNA and initiate translation, is sequestered within tertiary structural elements when the ligand is unbound and is made accessible after the riboswitch undergoes a ligand-induced conformational change. In translational repression, the SD is sequestered upon ligand binding.[18][16] The E. coli btuB AdoCbl riboswitch and  confirmed to regulate gene expression via a translational repression mechanism, as well as the env8 HyCbl riboswitch.[16]

Regulated Genes

edit

The cobalamin riboswitch is known to regulate a broad range of genes involved in cobalamin metabolism, including those genes coding for proteins involved in cobalamin biosynthesis and transport.[19] Examples include regulation of the btuB gene in E. coli which codes for a cobalamin transport protein,[1] regulation of CobA, an enzyme which converts uroporphyrinogen III to precorrin-2 during cobalamin biosynthesis in P. freudenreichiii,[20] and the cobalamin biosynthesis (cob) operon in S. typhimurium[21] among others.

Applications

edit

As drug targets

edit

The emerging threat of antibiotic resistance highlights the need for novel antibiotic development.[17] riboswitches, including cobalamin riboswitches, are currently being investigated as potential targets for novel antibiotics.[2] Not only do they regulate essential metabolic processes, they are also primarily found in prokaryotes. Only one riboswitch (the TPP riboswitch) has been identified in some plant cells to date, and no riboswitches have been identified in mammalian cells.[2][3] By targeting bacteria-specific regulatory mechanisms, the risk of host side-effects is minimized.[4] Furthermore, the mechanism in which a ligand binds to its riboswitch is inherently different from how a protein binds that same ligand, thus minimizing interference between the two systems.[16]

 
A basic schematic is shown here where the purple stars indicate the metabolite and the yellow arrow shows the reporter gene. The cells with a lower concentration of the metabolite have more riboswitches in the unbound state. The unbound conformation has an unstructured interaction between the ribosome binding site (RBS) and the blue and green segments. This unstructured interaction allows for the reporter gene to be translated efficiently downstream and produce a high signal output. At a higher metabolite concentration, the riboswitches form a bound conformation where the blue segment of the riboswitch interacts with the target RNA. This allows the green segment to interact with the RBS instead, and this allows the RBs to inhibit translation initiation of the reporter gene. Because of this, the signal output is lower than with the low concentration of the metabolite.

A bioinformatic study performed in 2019, which analyzed eight different riboswitch classes for suitability as antibacterial drug targets, classified the cobalamin riboswitch as being partially suitable for targeting with antibiotics.[2] As of 2019, cobalamin riboswitches were found in 5174 bacterial species, 7% of which are human pathogens.[2] The development of antibiotics targeting the cobalamin riboswitch is hindered due to the fact that not all cobalamin biosynthetic pathways are regulated by riboswitches, meaning that antibiotics targeting the riboswitch would need to be used in conjunction with additional drugs targeting alternative synthetic pathways in order to be effective.[2] As of 2021, no therapeutics targeting the cobalamin riboswitch are being developed.[5]

As biosensors

edit

Riboswitches are ideally suited to be engineered into biosensors due to their ability to undergo a conformational switch upon binding to specific ligands.[4] These sensors are constructed with a cobalamin riboswitch upstream of a gene encoding for a reporter molecule. The nature of the reporter molecule can vary depending on the desired detection method. For example, the reporter gene can encode for green fluorescent protein (GFP) when fluorescence-based detection methods are desired.[22] In the presence of ligand, the riboswitch undergoes a conformational change which blocks the ribosomal binding site, halting transcription of the reporter gene.

In 2010, researchers designed the first riboswitch-based AdoCbl sensor in E. coli.[4]  This sensor was also used to detect vitamin B12 biosynthetic precursors such as cobinamide and confirm the involvement of specific genes in cobalamin metabolism.[4] More recently, this sensor was used to screen Ensifer meliloti mutants for their ability to synthesize large quantities of Vitamin B12.[22] Riboswitch sensors can be utilized outside of a cellular environment. For example, a biosensor developed from a Propionibacterium freudenreichii cobalamin riboswitch was used to determine the vitamin B12 concentration in fermented food with high sensitivity.[23]

References

edit
  1. ^ a b c d Nahvi A, Sudarsan N, Ebert MS, Zou X, Brown KL, Breaker RR (September 2002). "Genetic control by a metabolite binding mRNA". Chemistry & Biology. 9 (9): 1043–1049. doi:10.1016/S1074-5521(02)00224-7. PMID 12323379.
  2. ^ a b c d e f g Pavlova N, Penchovsky R (July 2019). "Genome-wide bioinformatics analysis of FMN, SAM-I, glmS, TPP, lysine, purine, cobalamin, and SAH riboswitches for their applications as allosteric antibacterial drug targets in human pathogenic bacteria". Expert Opinion on Therapeutic Targets. 23 (7): 631–643. doi:10.1080/14728222.2019.1618274. PMID 31079546. S2CID 153306189.
  3. ^ a b Batey RT (April 2015). "Riboswitches: still a lot of undiscovered country". RNA. 21 (4): 560–563. doi:10.1261/rna.050765.115. PMC 4371280. PMID 25780138.
  4. ^ a b c d e f Aghdam EM, Hejazi MS, Barzegar A (November 2016). "Riboswitches: From living biosensors to novel targets of antibiotics". Gene. 592 (2): 244–259. doi:10.1016/j.gene.2016.07.035. PMID 27432066.
  5. ^ a b Panchal V, Brenk R (January 2021). "Riboswitches as Drug Targets for Antibiotics". Antibiotics. 10 (1): 45. doi:10.3390/antibiotics10010045. PMC 7824784. PMID 33466288.
  6. ^ a b c d e f g h i j Polaski JT, Webster SM, Johnson JE, Batey RT (July 2017). "Cobalamin riboswitches exhibit a broad range of ability to discriminate between methylcobalamin and adenosylcobalamin". The Journal of Biological Chemistry. 292 (28): 11650–11658. doi:10.1074/jbc.M117.787176. PMC 5512062. PMID 28483920.
  7. ^ Osman D, Cooke A, Young TR, Deery E, Robinson NJ, Warren MJ (January 2021). "The requirement for cobalt in vitamin B12: A paradigm for protein metalation". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1868 (1): 118896. doi:10.1016/j.bbamcr.2020.118896. PMC 7689651. PMID 33096143.
  8. ^ a b Barrick JE, Breaker RR (2007-11-12). "The distributions, mechanisms, and structures of metabolite-binding riboswitches". Genome Biology. 8 (11): R239. doi:10.1186/gb-2007-8-11-r239. PMC 2258182. PMID 17997835.
  9. ^ a b c d e Chan CW, Mondragón A (July 2020). "Crystal structure of an atypical cobalamin riboswitch reveals RNA structural adaptability as basis for promiscuous ligand binding". Nucleic Acids Research. 48 (13): 7569–7583. doi:10.1093/nar/gkaa507. PMC 7367189. PMID 32544228.
  10. ^ a b c Vitreschak AG, Rodionov DA, Mironov AA, Gelfand MS (September 2003). "Regulation of the vitamin B12 metabolism and transport in bacteria by a conserved RNA structural element". RNA. 9 (9): 1084–1097. doi:10.1261/rna.5710303. PMC 1370473. PMID 12923257.
  11. ^ Randle CL, Albro PW, Dittmer JC (September 1969). "The phosphoglyceride composition of Gram-negative bacteria and the changes in composition during growth". Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 187 (2): 214–220. doi:10.1016/0005-2760(69)90030-7. PMID 4898381.
  12. ^ Del Papa MF, Perego M (November 2008). "Ethanolamine activates a sensor histidine kinase regulating its utilization in Enterococcus faecalis". Journal of Bacteriology. 190 (21): 7147–7156. doi:10.1128/JB.00952-08. PMC 2580688. PMID 18776017.
  13. ^ Abreu-Goodger C, Merino E (July 2005). "RibEx: a web server for locating riboswitches and other conserved bacterial regulatory elements". Nucleic Acids Research. 33 (Web Server issue): W690–W692. doi:10.1093/nar/gki445. PMC 1160206. PMID 15980564.
  14. ^ Franklund CV, Kadner RJ (June 1997). "Multiple transcribed elements control expression of the Escherichia coli btuB gene". Journal of Bacteriology. 179 (12): 4039–4042. doi:10.1128/jb.179.12.4039-4042.1997. PMC 179215. PMID 9190822.
  15. ^ Weinberg Z, Wang JX, Bogue J, Yang J, Corbino K, Moy RH, Breaker RR (2010-03-15). "Comparative genomics reveals 104 candidate structured RNAs from bacteria, archaea, and their metagenomes". Genome Biology. 11 (3): R31. doi:10.1186/gb-2010-11-3-r31. PMC 2864571. PMID 20230605.
  16. ^ a b c d e Edwards AL, Batey RT (2010). "Riboswitches: A Common RNA Regulatory Element". Nature Education. 3 (9): 9.
  17. ^ a b Penchovsky R, Traykovska M (June 2015). "Designing drugs that overcome antibacterial resistance: where do we stand and what should we do?". Expert Opinion on Drug Discovery. 10 (6): 631–650. doi:10.1517/17460441.2015.1048219. PMID 25981754. S2CID 37080625.
  18. ^ Ariza-Mateos A, Nuthanakanti A, Serganov A (August 2021). "Riboswitch Mechanisms: New Tricks for an Old Dog". Biochemistry. Biokhimiia. 86 (8): 962–975. doi:10.1134/S0006297921080071. PMC 8961697. PMID 34488573. S2CID 237431666.
  19. ^ "Vitamin B-12". Mayo Clinic. Retrieved 2021-12-03.
  20. ^ Li J, Ge Y, Zadeh M, Curtiss R, Mohamadzadeh M (January 2020). "Regulating vitamin B12 biosynthesis via the cbiMCbl riboswitch in Propionibacterium strain UF1". Proceedings of the National Academy of Sciences of the United States of America. 117 (1): 602–609. Bibcode:2020PNAS..117..602L. doi:10.1073/pnas.1916576116. PMC 6955298. PMID 31836694.
  21. ^ Nahvi A, Barrick JE, Breaker RR (2004). "Coenzyme B12 riboswitches are widespread genetic control elements in prokaryotes". Nucleic Acids Research. 32 (1): 143–150. doi:10.1093/nar/gkh167. PMC 373277. PMID 14704351.
  22. ^ a b Cai Y, Xia M, Dong H, Qian Y, Zhang T, Zhu B, et al. (May 2018). "Engineering a vitamin B12 high-throughput screening system by riboswitch sensor in Sinorhizobium meliloti". BMC Biotechnology. 18 (1): 27. doi:10.1186/s12896-018-0441-2. PMC 5948670. PMID 29751749.
  23. ^ Zhu X, Wang X, Zhang C, Wang X, Gu Q (May 2015). "A riboswitch sensor to determine vitamin B12 in fermented foods". Food Chemistry. 175: 523–528. doi:10.1016/j.foodchem.2014.11.163. PMID 25577115.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cobalamin_riboswitch&oldid=1231916109"